Proteins and Peptides

24 July 2014

rEVO Biologics, Inc. Announces Enrollment of First Patient in Phase 3 Trial of ATryn® to Treat Early Onset Preeclampsia (PRESERVE-1)

24 July 2014

European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia

24 July 2014

PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis

24 July 2014

FDA accepts Sandoz application for biosimilar filgrastim

23 July 2014

Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society’s Journal “Bioconjugate Chemistry”

23 July 2014

ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome

22 July 2014

Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer

22 July 2014

Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH

22 July 2014

Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide

22 July 2014

ERYTECH Announces Enrollment of First Patient in Phase I/II Study of ERY-ASP in Acute Lymphoblastic Leukemia in the United States

21 July 2014

Maxwell Biotech Venture Fund’s Portfolio Company MetaMax Announces Enrollment of First Patients in Phase 1/2a Clinical Trial of its Lead Anticancer Drug MM-D37K

21 July 2014

Proteon Therapeutics Initiates Phase 3 Clinical Study of PRT-201 in Patients with Chronic Kidney Disease Undergoing Surgical Placement of an Arteriovenous Fistula for Hemodialysis

18 July 2014

Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis

17 July 2014

Dipexium Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Locilex® in Patients with Mild Infections of Diabetic Foot Ulcers

17 July 2014

Salix and Pharming Announce FDA Approval of RUCONEST® for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)

16 July 2014

Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA (BeneFIX®) Once-Weekly Prophylaxis For Hemophilia B

16 July 2014

Botulinum Neurotoxins: opportunities for biosimilars and biosuperiors to capture market shares

14 July 2014

Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation

11 July 2014

Sigma-Tau Rare Disease Submits Application to the European Medicines Agency (EMA) for Use of PegylatedL-Asparaginase (Oncaspar®) in the Treatment of Acute Lymphoblastic Leukaemia

11 July 2014

Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe1

10 July 2014

OPKO’s Long-Acting Clotting Factor VIIa-CTP Receives Positive Opinion For Three Orphan Drug Designations in Europe

10 July 2014

Adocia Announces Approval to Start a Phase IIa Clinical Study of HinsBet®, its Fast-acting Human Insulin, in Type 1 Diabetes

8 July 2014

Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo for Phase 3 Studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban

8 July 2014

FDA Approves NovoSeven® RT for the Treatment of Glanzmann’s Thrombasthenia (GT) With Refractoriness

8 July 2014

FDA Accepts Sanofi’s New Drug Application for Basal Insulin Toujeo

1 July 2014

Stage 3 Phase 2 Study of DARPin Abicipar Pegol (previously MP0112) Supports Progressing to Phase III Development Program

1 July 2014

Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

1 July 2014

Synageva BioPharma(TM) Reports Positive Top-Line Results From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency

30 June 2014

Nora Therapeutics Presents Phase 1 Data on NT100 at the European Society of Human Reproduction and Embryology Annual Meeting

30 June 2014

Allergan Announces R&D Pipeline Update and U.S. FDA Approval; Company to Host Conference Call Today, Monday, June 30th at 10:30 AM ET

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

PD-1 Agonists Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

FcRn Inhibitors Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review

DLL3-Targeted Immunotherapy Candidates Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

B7-H3-Targeted Immunotherapy Candidates Pipeline Review